Clinical Trial Update: Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the safety of tofacitinib, a JAK inhibitor, in primary Sjogren's syndrome; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjogren Syndrome

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) | Conditions: Sjogren's Syndrome | Phase 2 | Status: RECRUITING